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The pivotal role of interleukin-1 in the clinical
manifestations of rheumatoid arthritis
J.-M. Dayer
The role of the cytokine network in mediating inflammation and joint destruction in
rheumatoid arthritis (RA) has been investigated extensively in recent years. Interleukin-1
(IL-1) and tumour necrosis factor alpha (TNFα) are two pivotal proinflammatory cytokines
that have been shown to contribute to the clinical manifestations of RA. The ability of IL-1
to drive inflammation and joint erosion and to inhibit tissue repair processes has been clearly
established in in vitro systems and animal models. Under physiological conditions, the
activity of IL-1 is balanced by IL-1 receptor antagonist (IL-1Ra). Understanding of the
respective roles of IL-1 and IL-1Ra in conditions of health and disease has led to the
development of a recombinant IL-1ra, anakinra (Kineret®; Amgen Inc., Thousand Oaks,
CA), which offers a new therapeutic modality for RA.
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It is widely recognized that an interdependent network of
cytokines, including interleukin-1 (IL-1) and tumour
necrosis factor alpha (TNFα), plays a primary role in
mediating the pathophysiological processes underlying
inflammation and tissue destruction in rheumatoid
arthritis (RA). The development of therapeutic agents
for RA that target proinflammatory cytokines has added
an exciting new dimension to the management of this
disease. The US Food and Drug Administration (FDA)
and the European Commission have approved the use of
a recombinant human interleukin-1 receptor antagonist
(IL-1ra)—anakinra (Kineret®;  Amgen  Inc., Thousand
Oaks, CA), in patients with RA. In order to understand
the rationale for using such an agent to help counteract
the damaging cellular effects that occur in this disease,
several questions need to be addressed: (i) what is the
pathophysiological role of IL-1 in the processes of
inflammation, tissue destruction and tissue repair?
(ii) which of the deleterious effects of RA are specific
to IL-1 rather than other cytokines? (iii)  why  is the
inhibition of other cytokines not necessarily associated
with the inhibition of IL-1? and (iv) does IL-1 act in a
synergistic manner with other cytokines?
The pathophysiological role of IL-1 in RA
Synovial pannus formation is a characteristic of RA
pathology and is caused by several  processes: (i) the
proliferation of resident fibroblast-like synovial cells and
synoviocytes; (ii) angiogenesis; (iii) infiltration of
macrophages and lymphocytes; and (iv) migration of
polymorphonuclear cells to the synovial tissue. It has
been known for more than 20 yr that cell–cell interactions
between synoviocytes, lymphocytes and monocytes lead
to the production of large amounts of collagenase [1, 2].
It is now accepted that IL-1 and TNFα play an important
part in this process and act on endothelial cells, synovio-
cytes, chondrocytes, or bone-derived cells to produce
collagenase, other cytokines (e.g. IL-6), chemokines (e.g.
IL-8), or numerous prostanoids [e.g. prostaglandin E2
(PGE2)] [3–6].
IL-1—previously referred to by several different names,
including endogenous pyrogen, lymphocyte-activating
factor, mononuclear cell factor and catabolin—exerts
many systemic effects on tissues such as the brain, liver
and muscle. IL-1 is produced by cells in the joint
including chondrocytes and bone-lining cells—in-depth
immunohistochemistry and in situ hybridization studies
have revealed that IL-1 is localized to the synovial pannus
in RA, which is in close proximity to cartilage and bone
[7–9]. At a local level, relatively low concentrations of
IL-1 have extraordinary potential to induce cartilage
destruction and bone resorption. When equivalent molar
concentrations of IL-1 and TNFα have been compared,
IL-1 has been found to be more potent at inducing the
production of the tissue-destructive enzymes known as
matrix metalloproteinases (MMPs) [3, 10].
It is widely accepted that macrophages are the principal
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cells producing the prodestructive cytokines IL-1 and
TNFα [11, 12]. It is less clear which primary factors
control the production of IL-1 and TNFα by
macrophages. At least two major pathways exist: (i) the
cytokine-dependent pathway—induction of cytokine
release by T- or B-lymphocytes, mast cells, or soluble
factors (e.g. immune complexes or other cytokines such
as TNF) and (ii) the cytokine-independent pathways—
induction by direct contact between the macrophage and
activated T-lymphocytes, contact with denatured proteins
from the matrix and hormonal influences (Fig. 1). Taking
into account  our original studies, it appears that the
second pathway is more important in activating the
production of IL-1 and TNFα in synovial tissue in
patients with RA [13–15].
Two major and separate disease processes are
characteristic of RA:  (i)  inflammation  and pain and
(ii) tissue destruction and lack of tissue repair (Fig. 2;
Table 1). A number of mediators are implicated specific-
ally in these processes. Therefore, it is unlikely that a
single therapeutic agent would have beneficial effects on
both pathways. Indeed, one of the key challenges that
continues to face rheumatologists is how to both alleviate
inflammation and prevent joint destruction.
IL-1 is a key mediator of synovial inflammation and
pannus formation [12, 17, 18]. It is involved in the
inflammatory processes in RA through activation  of
monocyte–macrophages and T- and B-lymphocytes.
Although most investigations have focused on
T-lymphocytes, some recent studies of experimental
arthritis suggest that B-lymphocytes and a specific
antibody response may drive arthritis pathology also;
however, it remains to be seen if these models match
human disease [19, 20]. IL-1 also contributes to inflam-
mation by inducing the expression of   cell-adhesion
molecules, other cytokines, chemokines and chemokine
receptors, angiogenic factors and small inflammatory
mediators (e.g. PGE2 and nitric oxide) through the
stimulation of cyclo-oxygenase type 2 and inducible nitric
oxide synthase. Up-regulation of the production of
FIG. 1. Different pathways leading to IL-1 production by mono-
cyte–macrophages. Stimulation of monocyte–macrophages
(MΦ) to produce IL-1 can be cytokine dependent (e.g.
stimulation by   TNFα). However, contact   with activated
T-lymphocytes, denatured proteins and hormones may also
stimulate increased IL-1 production, independently of other
cytokines.
FIG. 2. IL-1 and TNFα are proinflammatory cytokines within the rheumatoid joint. IL-1 and TNFα are produced by cells within the
synovial pannus and act synergistically within the rheumatoid joint to up-regulate the production of small inflammatory mediators,
such as IL-6, IL-8 and PGE2. Furthermore, they increase the expression of adhesion molecules on the endothelium of high
endothelial venules, allowing the immigration of inflammatory cells into the joint space. IL-1 and TNFα also activate osteoclasts in
bone and stimulate the production of collagenase from chondrocytes [16]. Used with permission from Amgen Inc.
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prostaglandins  and other proinflammatory mediators
by IL-1 thereby accounts for some of the pain, swelling
and tenderness typically seen in rheumatoid joint
inflammation.
IL-1 is a pivotal cytokine mediating destruction of
bone and cartilage in RA and additionally impairs bone
and cartilage repair [21–23]. Effects of IL-1 on these
parameters appear to be more profound than those of
TNFα. IL-1 induces the proliferation of synovial cells
and   an increase   in   the   production of MMPs by
chondrocytes and synovial cells, resulting in cartilage
degradation. The cytokine also inhibits cartilage repair
through inhibition of matrix protein synthesis [24–26].
In terms of bone erosion, IL-1 causes an increase in
expression of the receptor activator of nuclear factor-κB
ligand (RANKL), which, in turn, stimulates the
differentiation and activation of osteoclasts (the cells
responsible for bone resorption), leading to an increase in
bone turnover [27].
Relative roles of IL-1 and TNFα in inflammation
and destruction
Numerous studies based on various animal models of
arthritis (including antigen-induced, collagen-induced,
immune complex, or streptococcal-cell-wall-induced
arthritis) have investigated the relative importance of
IL-1 and TNFα in the processes of inflammation and
destruction. These studies have been reviewed in detail by
Wim van den Berg (Table 2) [28]. This analysis constitutes
a semi-quantitative appreciation of the global results
obtained from many different experimental conditions;
nevertheless, it is evident that, in some models of
arthritis, TNFα appears to have a greater inflammatory
effect than IL-1, while IL-1 appears to have a greater
inflammatory effect in others. What appears to be
consistent in animal studies, however, is that IL-1 plays a
more important role in the destructive processes of
arthritis, presumably due to its extremely potent ability
to inhibit the  tissue repair process. Synthesis of new
matrix proteins in cartilage—such as collagen type II
or aggrecans—and proliferation of chondrocytes are
necessary for cartilage repair and all of these processes
are inhibited by IL-1. In fact, we found that IL-1 strongly
inhibited the new synthesis of glycosaminoglycans in
human cartilage [24]. When compared on a molar basis in
this system, the inhibition by IL-1 was much stronger
than that afforded by TNFα (which had a very small
effect) and interferon-γ (which had no effect at all). Of
importance, the inhibitory effect of IL-1 on this repair
process was restored when IL-1Ra was added at adequate
concentrations [29].
Regulation of IL-1
The relative concentrations of agonistic and antagonistic
cytokines establish a delicate balance in driving pro- and
anti-inflammatory processes. There are currently 10
different gene products identified in the IL-1 superfamily.
Three of these have been extensively studied for their role
in disease: IL-1α (a predominantly intracellular agonist);
IL-1β (a secreted agonist); and IL-1Ra (a secreted
antagonist). IL-1 can be antagonized in at least four
different ways: (i) by IL-1Ra, which is a true endogenous
receptor antagonist; (ii) by soluble receptors that are
cleaved on the surface of  the cells (IL-1sRII); (iii) by a
so-called ‘decoy’ receptor (IL-1RII), which lacks an
intracellular signalling domain and, thus, is not capable
of signal transduction; and (iv) by natural autoantibodies
to IL-1, particularly to IL-1α [30, 31].
Both IL-1α and IL-1β bind to the membrane-bound
IL-1 type I receptor (IL-1RI), leading to the recruitment
of   the IL-1 receptor accessory protein (IL-1RAcP;
Fig. 3). This heterotrimeric complex transduces a signal
to the cell nucleus, culminating in production of
inflammatory and destructive mediators [4].
IL-1Ra is the most important physiological regulator
of synovial IL-1 activity [32]. IL-1Ra has a high affinity
for the IL-1RI; however, binding of the inhibitory protein
to the receptor does not allow the recruitment of the
IL-1RAcP, thus there is no signal transduction [33]. The
strong binding of IL-1Ra to IL-1RI blocks the access
of IL-1α and IL-1β to the receptor [4]. Cleaved fragments
of the IL-1RII receptor (IL-1sRII) also inhibit the
action of IL-1, by binding to circulating IL-1. Finally,
IL-1 can be trapped on the cell surface by the membrane-
bound ‘decoy’ IL-1RII [34]. The different inhibitory
mechanisms are quite complementary, with in vitro
TABLE 1. The involvement of IL-1 in the inflammatory and
destructive processes of RA






Increased expression of cell
adhesion molecules
Increased production of MMPs
by chondrocytes and synovial cells
Increased expression of cytokine




chemokines and angiogenic factors
Increased expression of PGE2,
nitric oxide and COX-2
Inhibition of proteoglycan and
type II collagen synthesis resulting
in impaired cartilage repair
Resorption of bone by activation
of osteoclasts
TABLE 2. Cytokine involvement in inflammation and destruction:
studies in TNFα- or IL-1-deficient mice [28]
Murine model of arthritis
Inflammation Destruction
TNFα IL-1 TNFα IL-1
Antigen-induced ++ + – +++
Collagen-induced ++ +++ + +++
Immune complex + +++ – +++
Streptococcal-cell-wall-
induced
++ + – +++
–, no cytokine involvement; +, minimal cytokine involvement;
++, moderate cytokine involvement; +++ greatest cytokine involvement.
Table used with permission of Seminars in Arthritis and Rheumatism.
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studies on human synoviocytes showing that the simul-
taneous addition of both IL-1Ra and soluble IL-1sRII
strongly inhibits the IL-1-induced production of MMP
and PGE2 [35].
Milestones in the discovery of IL-1Ra
The histochemical discovery of IL-1Ra took place at
the beginning of the 1980s, when we were undertaking
the isolation of large quantities of IL-1 (which had not
yet been cloned), using an IL-1 synovial cell bioassay
based on the stimulation of collagenase and PGE2.
No immunoassays were available at the time. Our
investigations focused on diseases associated with large
numbers of monocytes (such as monocytic leukaemia)
and chronic debilitating diseases (such as RA and
juvenile RA). Our attention also focused on diseases with
spontaneous remission of fever, since we suspected the
presence of natural inhibitors that reversed the peak of
fever. To our surprise, we failed to detect any biological
activity of IL-1 in serum or urine of seriously ill patients
with one of the above diseases [36–38]. This gave rise to
the hypothesis that IL-1 activity may be masked by an
inhibitory molecule and that concentrations of such an
inhibitory molecule must be considerably elevated during
fever remission. This was confirmed when the fever
profile of juvenile RA patients was analysed [39]. A
protein with a mol. wt of ~17 kDa was partially purified
from the urine of afebrile patients; this was found
specifically to inhibit the biological activities of IL-1
without affecting those of TNFα [40, 41]. Around the
same time, Arend and co-workers [42] made the
independent observation of an inhibitor of chondrocyte
and thymocyte responsiveness to IL-1 in cultured human
monocytes. It should be recognized that at the time the
mechanism of action for this IL-1 inhibitor had not yet
been identified. Indeed, the first description of the
protein giving rise to the nomenclature of ‘receptor
antagonist’ originated from our ligand-binding assay
reported in 1987, revealing that a natural, purified
molecule was impeding the binding of IL-1 to lympho-
cytes [43].
Based on the inhibiting effect of natural IL-1Ra on the
binding of IL-1 to lymphocytes, IL-1Ra was fully purified
and cloned at Synergen in 1990 [44, 45]. DNA encoding
the IL-1Ra protein was obtained from a human
monocyte library and the endogenous IL-1Ra partially
purified from the urine of patients was found  to be
similar to recombinant IL-1Ra [41, 46].
An important aspect of the inhibitory effect of IL-1Ra
was observed in 1990 during studies conducted in our
laboratory in collaboration with Larry Raisz. It was
observed that recombinant IL-1Ra blocked IL-1-induced
bone resorption in vitro, as determined by calcium release
from a model of bone resorption (Fig. 4) [46]. Notably,
recombinant IL-1Ra was not found to block the
resorption induced by parathyroid hormone, suggesting
that this inhibitory protein does not disturb the bone
resorptive effects of the parathyroid hormone system or
calcitonin homeostasis. Bendele et al. [47] demonstrated
subsequently that IL-1Ra markedly decreased bone
FIG. 3. Regulation of IL-1 biological activity. (A) IL-1 binds to
IL-1RI, leading to the formation of a heterotrimeric complex
with IL-1RAcP and transduction of a signal to the cell nucleus.
(B) IL-1Ra binds to  IL-1RI; however, IL-1RAcP is unable
to bind and, thus, signal transduction does not occur.
(C) Circulating IL-1 is trapped by IL-1sRII and is thus unable
to bind to IL-1RI. IL-1 can also bind to membrane-associated
IL-1RII, known as a ‘decoy’ receptor, as it has no intracellular
signalling domain.
FIG. 4. IL-1Ra blocks IL-1-induced bone resorption in vitro.
This graph shows the degree of bone resorption associated with
IL-1  in  neonatal mouse calvariae. Resorption was tested in
calvariae from 7-day-old mice and was assessed by measuring
the release of previously incorporated 45Ca. In calvariae not
treated with IL-1Ra (open triangles), an increase in bone
resorption was observed with recombinant IL-1 concentrations
as low as 0.01 ng/ml. In calvariae treated with recombinant
IL-1Ra at 1000 ng/ml (black triangles), the increase in
IL-1-mediated bone resorption was blocked. The increase in
45Ca release by parathyroid hormone (light grey triangles) was
not affected by recombinant IL-1Ra (dark grey triangles),
suggesting that IL-1Ra does not disturb the bone resorptive
effects  of parathyroid  hormone [46].  Reproduced  with per-
mission from The Journal of Immunology. ©1990 The American
Association of Immunologists Inc.
ii6 J.-M. Dayer
resorption in rats with collagen-induced arthritis, as
substantiated by histopathological results (Fig. 5).
The importance of IL-1Ra in counteracting the
destructive effects of IL-1 has been demonstrated in mice
deficient in the IL-1Ra gene. Such animals have been
found to spontaneously develop arthritis. A specific
example is the BALB/cA murine model of arthritis, in
which animals developed marked inflammatory poly-
arthropathy that closely mimics human RA [48]. The
animals also had distinct erosion of the articular bone.
These findings suggest that endogenous IL-1Ra down-
regulates inflammatory synovitis and joint destruction
by inhibiting IL-1, reducing the signs and symptoms
of inflammation and preventing bone and cartilage
destruction.
Interestingly, the phenotype of IL-1Ra-deficient mice
appears to depend on genetic background; mice with
certain genetic backgrounds presented with arthritis and
bone destruction [48], while mice with a different genetic
background developed vasculitis [49]. This observation is
likely to have important clinical implications in the future
when assessing the response of patients to various RA
therapies, which may depend on the patients’ genetic
background.
Independent pathways of cytokine production
During recent years, there has been a great deal of
contention about the disparate effects of IL-1 and TNFα
in arthritic processes.   Existing data   from in   vitro
experiments and animal models indicate that IL-1
production can be induced independently of TNFα and
this is also supported by the observation that not all RA
patients respond to anti-TNF therapy. Certainly, TNFα
can induce macrophages to produce IL-1, but IL-1 can
also (at least to some degree) induce macrophages to
produce more IL-1 and TNFα. There are also a number
of other pathways and factors that may activate IL-1
production from monocytes, independent of TNFα, such
as the contact between T-cells, denatured matrix proteins,
hormones and possibly neuropeptides (Fig. 1). Strong
evidence from in vitro systems suggests that the contact
between T-cells and monocyte–macrophages is a major
pathway for the induction of IL-1 and TNFα [13–15, 50,
51]. This interaction can be decreased by impeding
different ligand–counterligand interactions (e.g. CD69,
β2-integrin and apolipoprotein A-I) [14, 52–54]. It follows
that, depending on factors such as type of disease, type
of stimuli, animal model, or subset of patients, either
the IL-1 or TNFα pathway will dominate and lead to
different specific manifestations of the disease.
Synergism between IL-1 and TNFα
Although it is evident that IL-1 and TNFα have inde-
pendent roles in mediating some of the pathophysio-
logical processes of RA, it is also apparent that these
cytokines act in a synergistic manner. This was illustrated
in a study of rats with collagen-induced arthritis that were
administered IL-1ra alone, anti-TNF alone, or IL-1ra in
combination with anti-TNF. Inflammation and bone
resorption were both counteracted to some degree with
either agent alone, compared with control animals.
However, the most striking effects were observed in
animals receiving the combination treatment [55].
Clinical studies of combination therapy are in progress to
assess safety and efficacy in patients with RA [56, 57].
The goal for the future is to elucidate markers that
can discriminate and predict the response to treatment
with different biological response modifiers, such as IL-1
and TNF inhibitors. This could include use of genetic
polymorphism profiling or genetic expression profiling
[58, 59]. However, no definite conclusions can be made
for the time being.
Conclusions
In conclusion, the pathogenesis of inflammatory
synovitis and rheumatoid joint destruction is mediated by
an interdependent network of cytokines. IL-1 and TNFα
clearly play central roles in  the processes underlying
the pathogenesis of RA, as summarized in Fig. 6. It is
also evident, however, that there are quantitative differ-
ences between these two cytokines. For example, TNFα
appears to have a stronger influence in the context of
inflammation, while IL-1 is stronger than TNFα in
stimulating production of MMPs and in impairing the
synthesis of collagen and proteoglycans. These differ-
FIG. 5.  Effects of IL-1Ra  on  bone resorption in  rats with
arthritis induced by collagen type II. Rats were treated with
different concentrations of IL-1Ra by continuous subcutaneous
infusion for 7 days. (A) Bone resorption or damage was assessed
by measuring trabecular and cortical bone resorption and
the number of  osteoclasts. (B) Total histopathological assess-
ment represents the evaluation of inflammation, pannus
formation (caliper measurements, paw weights, inflammatory
cell infiltration), cartilage damage (toluidine blue staining)
and bone damage. Interleukin-1 receptor antagonist (IL-1Ra)
produced dose-dependent reductions in bone resorption in
rats  with arthritis  induced by collagen type II. Reductions
were statistically significant compared with vehicle with IL-1Ra
1 and 5 mg/kg/h (P < 0.05). Figure adapted from Bendele et al.
[47].
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ences have importance when evaluating therapy options
for different patients, taking into account their clinical
symptoms, stage of disease and genetic background.
The development of agents that specifically  target
cytokines marks a new therapeutic era for the manage-
ment of RA. The respective effects of IL-1 and TNFα in
inflammation and tissue destruction require further
in-depth comparison and a great deal will be learned
from the current trials of combination therapy. However,
experimental data support the claim that IL-1 is a pivotal
cytokine involved in the pathophysiology of RA and
thus is an attractive target, not only for prevention of
joint destruction, but also to safeguard repair processes.
Such observations indicate that recombinant IL-1ra will
be a useful addition to the existing RA management
approaches.
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